The FDA has scheduled an Oncologic Drugs Advisory Committee hearing for May 14, 2019, to discuss a new drug application for pexidartinib for the treatment of adult patients with symptomatic tenosynovial giant cell tumor.
Matthew S. Davids, MD, MMSc, discusses recent shifts in the chronic lymphocytic leukemia paradigm with the use of novel therapies and the need to increase personalized treatment with these agents.
Giada Bianchi, MD, discusses the scope of frontline therapy and subsequent maintenance strategies among patients with transplant eligible and ineligible newly diagnosed multiple myeloma.
Michael J. Overman, MD, discusses an immunotherapy combination regimen in metastatic colorectal cancer and highlights existing challenges that still need to be addressed in future research.
Investigational data are associated with folate receptor alpha-targeting agents, with an emphasis on the recent development and therapeutic potential of antibody-drug conjugates for the treatment of patients with ovarian cancer.
Mariana Chavez Mac Gregor, MD, MSc, discussex recent shifts in the treatment of patients with metastatic triple-negative breast cancer.
Leonard G. Gomella, MD, underscores the need for genetic testing in prostate cancer, sheds light on important biomarkers in the space, and explains how these tests are helping oncologists facilitate a precision medicine approach.
Although biological criteria carry prognostic value in mantle cell lymphoma, initial observation based solely on clinical criteria was found to be an effective management strategy that did not compromise patient outcomes.
Cindy Osborne, MD, highlights the many advances that have been made in the treatment paradigms of locally advanced and metastatic HER2-positive breast cancer.
Kathleen N. Moore, MD, discusses the potential impact of antibody-drug conjugates on outcomes for patients with ovarian cancer.